This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Hoering, A. Articles by Crowley, J. J. PubMed PubMed Citation Articles by Hoering, A. Articles by Crowley, J. J.

Randomized Phase III Clinical Trial Designs for Targeted Agents

Authors' Affiliations: ¹ Fred Hutchinson Cancer Research Center, Southwest Oncology Group Statistical Center and ² Cancer Research and Biostatistics, Seattle, Washington

Requests for reprints: Antje Hoering, Cancer Research and Biostatistics, 1730 Minor Avenue, Seattle, WA 98101. Phone: 206-839-1789; Fax: 206-652-4612; E-mail: antjeh{at}crab.org.

Abstract

Purpose: Cancer therapies with mechanisms of action which are very different from the more conventional chemotherapies are now being developed. In this article, we investigate the performance of several phase III clinical trial designs, both for testing the overall efficacy of a targeted agent and for testing its efficacy in a subgroup of patients with a tumor marker present. We study different designs and different underlying scenarios assuming continuous markers, and assess the trade-off between the number of patients on the study and the effectiveness of treatment in the subgroup of marker-positive patients.

Experimental Design: We investigate binary outcomes and use simulation studies to determine sample size and power for the different designs and the various scenarios. We also simulate marker prevalence and marker misclassification and evaluate their effect on power and sample size.

Results: In general, a targeted design which randomizes patients with the appropriate marker status performs the best in all scenarios with an underlying true predictive marker. Randomizing all patients regardless of their marker values performs as well as or better in most cases than a clinical trial that randomizes the patient to a treatment strategy based on marker value versus standard of care.

Conclusion: If there is the possibility that the new treatment helps marker-negative patients, or that the cutpoint determining marker status has not been well established and the marker prevalence is large enough, we recommend randomizing all patients regardless of marker values, but using a design such that both the overall and the targeted subgroup hypothesis can be tested.